Ebos JM - Search Results

1

Modeling spontaneous metastatic renal cell carcinoma (mRCC) in mice following nephrectomy.

Tracz A, Mastri M, Lee CR, Pili R, Ebos JM. Tracz A, et al. Among authors: ebos jm. J Vis Exp. 2014 Apr 29;(86):51485. doi: 10.3791/51485. J Vis Exp. 2014. PMID: 24836396 Free PMC article.

2

Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy.

Ebos JM, Lee CR, Christensen JG, Mutsaers AJ, Kerbel RS. Ebos JM, et al. Proc Natl Acad Sci U S A. 2007 Oct 23;104(43):17069-74. doi: 10.1073/pnas.0708148104. Epub 2007 Oct 17. Proc Natl Acad Sci U S A. 2007. PMID: 17942672 Free PMC article.

3

Vascular endothelial growth factor-mediated decrease in plasma soluble vascular endothelial growth factor receptor-2 levels as a surrogate biomarker for tumor growth.

Ebos JM, Lee CR, Bogdanovic E, Alami J, Van Slyke P, Francia G, Xu P, Mutsaers AJ, Dumont DJ, Kerbel RS. Ebos JM, et al. Cancer Res. 2008 Jan 15;68(2):521-9. doi: 10.1158/0008-5472.CAN-07-3217. Cancer Res. 2008. PMID: 18199548

4

Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis.

Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Ebos JM, et al. Cancer Cell. 2009 Mar 3;15(3):232-9. doi: 10.1016/j.ccr.2009.01.021. Cancer Cell. 2009. PMID: 19249681 Free PMC article.

5

Dose-dependent increases in circulating TGF-alpha and other EGFR ligands act as pharmacodynamic markers for optimal biological dosing of cetuximab and are tumor independent.

Mutsaers AJ, Francia G, Man S, Lee CR, Ebos JM, Wu Y, Witte L, Berry S, Moore M, Kerbel RS. Mutsaers AJ, et al. Among authors: ebos jm. Clin Cancer Res. 2009 Apr 1;15(7):2397-405. doi: 10.1158/1078-0432.CCR-08-1627. Epub 2009 Mar 10. Clin Cancer Res. 2009. PMID: 19276250

6

Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy.

Ebos JM, Lee CR, Kerbel RS. Ebos JM, et al. Clin Cancer Res. 2009 Aug 15;15(16):5020-5. doi: 10.1158/1078-0432.CCR-09-0095. Epub 2009 Aug 11. Clin Cancer Res. 2009. PMID: 19671869 Free PMC article. Review.

7

Mind the gap: potential for rebounds during antiangiogenic treatment breaks.

Ebos JM, Pili R. Ebos JM, et al. Clin Cancer Res. 2012 Jul 15;18(14):3719-21. doi: 10.1158/1078-0432.CCR-12-1459. Epub 2012 Jun 7. Clin Cancer Res. 2012. PMID: 22679177

8

Preclinical recapitulation of antiangiogenic drug clinical efficacies using models of early or late stage breast cancer metastatis.

Kerbel RS, Guerin E, Francia G, Xu P, Lee CR, Ebos JM, Man S. Kerbel RS, et al. Among authors: ebos jm. Breast. 2013 Aug;22 Suppl 2:S57-65. doi: 10.1016/j.breast.2013.07.011. Breast. 2013. PMID: 24074794 Free article. Review.

9

Classical mathematical models for description and prediction of experimental tumor growth.

Benzekry S, Lamont C, Beheshti A, Tracz A, Ebos JM, Hlatky L, Hahnfeldt P. Benzekry S, et al. Among authors: ebos jm. PLoS Comput Biol. 2014 Aug 28;10(8):e1003800. doi: 10.1371/journal.pcbi.1003800. eCollection 2014 Aug. PLoS Comput Biol. 2014. PMID: 25167199 Free PMC article.

10

Neoadjuvant antiangiogenic therapy reveals contrasts in primary and metastatic tumor efficacy.

Ebos JM, Mastri M, Lee CR, Tracz A, Hudson JM, Attwood K, Cruz-Munoz WR, Jedeszko C, Burns P, Kerbel RS. Ebos JM, et al. EMBO Mol Med. 2014 Dec;6(12):1561-76. doi: 10.15252/emmm.201403989. EMBO Mol Med. 2014. PMID: 25361689 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

42 results

Search Page

Filters